Attention healthcare providers!
There are three excellent online educational opportunities that can be completed for accreditation through October 31st – that’s less than 30 days from now so don’t delay!
All…
NHF and HFA have been provided the following statement from CSL Behring.
NHF and HFA remind you to please reach out to your physician with any medical concerns. You can also contact CSL Behring’s Medical Information Phone…
The recent news about the passing of United State Supreme Court Justice Ruth Bader Ginsburg and nomination of Judge Amy Coney Barrett to replace her have brought the Supreme Court and a pending Affordable Care Act (ACA) lawsuit to the headlines and…
Objective:
Hemophilia is a congenital deficiency in a clotting factor resulting in a propensity for severe and disabling bleeds. Joint bleeds can lead to disabling arthropathy and past contamination of blood products resulted in…
We are delighted to announce that the research poster abstracts exhibited virtually at this summer’s 72nd BDC are now available on the NHF website. A long-time staple of BDC, these abstracts highlight the many important research projects happening…
A recent commentary published in the journal Haemophilia, posits that while clinical trials for hemophilia gene therapy approach conclusion, there remain significant unanswered questions and lingering concerns that can only be addressed through…
Sanofi recently announced results from their phase 1/2a EXTEN-A trial for their investigational therapy BIVV001, which were published in the New England Journal of Medicine (NEJM).
BIVV001 is a novel recombinant factor VIII therapy (rFVIII)…
NHF is working with the bleeding disorders community to envision our future for the next decade, and we need your input. Earlier this summer, we conducted teleconferences, co-moderated by NHF President and CEO Leonard Valentino, MD, with members of…
CSL Behring recently announced that they are discontinuing Mononine®, the company’s human plasma-derived factor therapy indicated for the prevention and control of bleeding in patients with hemophilia B. They noted the modest number of patients…
The National Hemophilia Foundation will be holding our quarterly Board of Directors meeting on Saturday, October 10th at 9:00 AM EDT. The Board of Directors meeting is open to the public.